RTTNews | Sep 7, 2020 03:04AM EDT

03:04 Monday, September 7, 2020 (RTTNews.com) - Grifols (GRFS) has agreed to acquire the remaining equity of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis. The closing of the deal is anticipated in early 2021.

In addition to the clinical development of specific plasma fractions and protein inhibitors, Alkahest is focused on developing a complete understanding of the human plasma proteome. Alkahest, as a wholly owned subsidiary within the Grifols innovation office, will focus on proteins with biological impact that change with age.

Read the original article on RTTNews ( https://www.rttnews.com/3126481/grifols-to-acquire-remaining-stock-of-alkahest-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved